Corporate | 6 December 2011 07:30
|
4SC AG / Key word(s): Miscellaneous
Press Release 4SC to present clinical development programme with lead cancer drug Resminostat at World Epigenetics Summit Planegg-Martinsried, Germany, 6 December 2011 – 4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the company will present the clinical Phase II programme with its lead anti-cancer compound resminostat at the 2 nd World Epigentics Summit from 6-8 December 2011 in Munich. Dr. Bernd Hentsch, 4SC's Chief Development Officer, will give the oral presentation on 8 December 2011 at 4:15 pm (CET). Resminostat is an oral pan-histone-deacetylase (HDAC) inhibitor which, as a novel targeted cancer therapeutic, is designed to cause differentiation of tumour cells and programmed cell death (apoptosis) by modifying tumour cells' DNA structure. Resminostat is currently being clinically developed in three different cancer indications: hepatocellular carcinoma (HCC), which is the most common type of liver cancer, colorectal cancer (CRC), and Hodgkin's lymphoma (HL), a cancer of the lymphatic system. The compound has shown a very good safety profile and promising anti-tumour activity in pre-clinical and clinical development up to clinical Phase II trials. After recently having published positive data from a Phase II study with resminostat in HL patients, 4SC expects to publish results of a Phase II study with resminostat in HCC at the beginning of 2012. Currently the company is preparing for discussions of the next development steps with regulatory authorities and potential partners, which – considering the high medical need and the limited therapeutic options available in the cancer indications addressed with resminostat – is expected to be a pivotal development programme. From 8 December 2011, 4:15 pm (CET), the detailed presentation of Dr. Hentsch at the World Epigentics Summit will be available for download at http://www.4sc.de/product-pipeline/publications-posters/resminostat . Ends About Resminostat Resminostat (4SC-201) is an oral pan-histone-deacetylase (HDAC) inhibitor. HDAC inhibitors modify the DNA structure of tumour cells to cause their differentiation and programmed cell death (apoptosis) and are therefore considered to offer a mechanism of action that has the particular potential to halt tumour progression and induce tumour regression. Resminostat is currently being investigated in the Phase II SHELTER study as a second-line treatment for advanced hepatocellular carcinoma (HCC) and in the Phase I/II SHORE study as a second-line treatment in colorectal cancer in KRAS-mutant patients. The Phase II SHELTER study is expected to report results in the beginning of 2012. Initial results of the SHORE study are expected in 2012. With an overall response rate of 35.3% and a clinical benefit in 55.9% of the patients, the Phase II SAPHIRE trial with resminostat as a monotherapy in advanced Hodgkin's lymphoma has demonstrated the drug's substantial anti-tumour activity in a heavily pre-treated patient population together with very good safety and tolerability. The study is still ongoing as one further patient is still continuing therapy and has currently achieved stabilization of disease for more than 30 weeks in the optional follow-up phase beyond the study's main treatment part of 12 weeks. About 4SC 4SC (ISIN DE0005753818) discovers and develops targeted small-molecule drugs for the treatment of diseases with a high unmet medical need in various autoimmune and cancer indications. These drugs are intended to provide patients with innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The company's balanced pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with leading pharmaceutical companies. Founded in 1997, 4SC currently has 94 employees and has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005. Legal Note This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors. For more information please visit www.4sc.com or contact:
4SC AG
Bettina v. Klitzing-Stückle, Corporate Communications
MC Services (Europe)
Mareike Mohr
The Trout Group (USA)
End of Corporate News 06.12.2011 Dissemination of a Corporate News, transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
| Language: | English | |
| Company: | 4SC AG | |
| Am Klopferspitz 19a | ||
| 82152 Martinsried | ||
| Germany | ||
| Phone: | +49 (0)89 7007 63-0 | |
| Fax: | +49 (0)89 7007 63-29 | |
| E-mail: | public@4sc.com | |
| Internet: | www.4sc.de | |
| ISIN: | DE0005753818 | |
| WKN: | 575381 | |
| Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart | |
| End of News | DGAP News-Service |
|
|
| 148461 06.12.2011 |